A recent study in February 2017 by American Academy of Neurology has shown that Eptinezumab can significantly reduce the impact of chronic migraine on daily functioning at weeks 5 through 10 following just one infusion. Formerly called ALD403, its an investigational monoclonal antibody that works fast.
This drug significantly reduced number of migraine days in a group of 50 patients with chronic migraine.
The study included 588 adults with chronic migraine who were randomized to placebo or eptinezumab. All patients had headaches on ≥16 of every 26 days, including ≥6 migraine attacks and ≥9 migraine days.
The study was carried out in phases, and phase IIb successfully evaluated scores on headache impact test-6 (HIT-6) from baseline to week 10 in chronic migraine patients, where each group got a single intravenous infusion of eptinezumab in varying doses (300mg, 100mg, 30mg, 10mg, or placebo).
The findings were reported by Dr. Richard Lipton and his colleagues of Albert Einstein College of Medicine in New York.
All doses of eptinezumab were well tolerated, and no serious treatment-related adverse events were reported. This shows Eptinezumab reduces migrianes.